Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies

Biometrical Journal
Pavel Mozgunov, Thomas Jaki, Xavier Paoletti
DOI
10.1002/bimj.201900332